| Prev Close | 12.50 |
| Day Low/High | 12.45 / 13.09 |
| 52 Wk Low/High | 6.75 / 15.46 |
| Avg Volume | 921.50K |
Intra-Cellular Therapies Inc. (ITCI)
12.82
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 55.26M |
| Market Cap | 690.76M |
| EPS | -2.80 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
2 Attractive Biotechs With Key Study Outcomes on the Horizon
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
China Trade Truce, Biotech Fuel Action
Markets continue to be nicely in the black two hours into trading as resumption of U.S.-China trade talks have investors in a good mood to start off the second half of trading in 2019. Some small biotechs continue to show some strength this Monday. ...
2 Biotech Names See Directors Direct Cash to Their Shares
The stock purchases by the insiders are at companies developing treatments for breast cancer and schizophrenia.
Two to Buy on the Dip
Talk of intensifying trade war is creating some bargains for investors.
The January Effect Is on Time This Year
I continue to believe that biotech and biopharma stocks will outperform in 2018.
DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers
The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.
2 Small Biopharmas With Case of 'Hiccups'
Insiders are taking advantage of opportunities in Intra-Cellular Therapies and Aldeyra.
3 Small Biotech Stocks Insiders Are Buying
Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.
Could These 9 Drugs Gain FDA Approval in the Age of Trump?
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
The firms all have drugs they want the feds to bend the rules to approve.
Shares of Intra-Cellular Plummet in Thursday's Trading Session
Shares of Intra-Cellular Therapies plummeted on Thursday as the biopharmaceutical company's phase three trial of its schizophrenia drug was unsuccessful.
Rev's Forum: Beating the Bushes for Some Good Trade Ideas
Here are 4 stocks to take a look at as this hot-money action picks up.
Stock Strategy: Finding the Right Entry Point
If you miss the boat, consider a plan B, like buying on the open or looking for available weakness.
Market Wrap: Rally Rules as Fed Looms
Second straight day of gains for stock market.